BR112023016904A2 - Preparação da proteína de ligação à siglec-15 e uso da mesma - Google Patents

Preparação da proteína de ligação à siglec-15 e uso da mesma

Info

Publication number
BR112023016904A2
BR112023016904A2 BR112023016904A BR112023016904A BR112023016904A2 BR 112023016904 A2 BR112023016904 A2 BR 112023016904A2 BR 112023016904 A BR112023016904 A BR 112023016904A BR 112023016904 A BR112023016904 A BR 112023016904A BR 112023016904 A2 BR112023016904 A2 BR 112023016904A2
Authority
BR
Brazil
Prior art keywords
binding protein
siglec
preparation
same
antigen
Prior art date
Application number
BR112023016904A
Other languages
English (en)
Inventor
Chunyin Gu
Lu Yang
Peipei Liu
Sujun Deng
Xiaodan Cao
Xiaowu Liu
Xinxiu Yang
Xueping Wang
Zhongzong Pan
Zongda Wang
Original Assignee
Jiangxi Jemincare Group Co Ltd
Shanghai Jemincare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Jemincare Group Co Ltd, Shanghai Jemincare Pharmaceutical Co Ltd filed Critical Jiangxi Jemincare Group Co Ltd
Publication of BR112023016904A2 publication Critical patent/BR112023016904A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

preparação da proteína de ligação à siglec-15 e uso da mesma. a presente invenção provê uma preparação de uma proteína de ligação à siglec-15 e uso da mesma, e se refere especificamente a uma proteína de ligação ao antígeno isolada, que compreende hcdr3. é provido o uso da proteína de ligação ao antígeno na prevenção e tratamento de doenças.
BR112023016904A 2021-02-23 2022-02-22 Preparação da proteína de ligação à siglec-15 e uso da mesma BR112023016904A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110202065 2021-02-23
PCT/CN2022/077193 WO2022179483A1 (zh) 2021-02-23 2022-02-22 Siglec-15结合蛋白的制备及其用途

Publications (1)

Publication Number Publication Date
BR112023016904A2 true BR112023016904A2 (pt) 2023-11-07

Family

ID=83047766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016904A BR112023016904A2 (pt) 2021-02-23 2022-02-22 Preparação da proteína de ligação à siglec-15 e uso da mesma

Country Status (11)

Country Link
US (1) US20240124576A1 (pt)
EP (1) EP4299591A1 (pt)
JP (1) JP2024508048A (pt)
KR (1) KR20230148420A (pt)
CN (1) CN116867807A (pt)
AU (1) AU2022225026A1 (pt)
BR (1) BR112023016904A2 (pt)
CA (1) CA3209169A1 (pt)
IL (1) IL305409A (pt)
TW (1) TW202235436A (pt)
WO (1) WO2022179483A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2868959A1 (en) * 2012-03-30 2013-10-03 Daiichi Sankyo Company, Limited Cdr-modified anti-siglec-15 antibody
CN110386982A (zh) * 2019-04-09 2019-10-29 广东三九脑科医院 鼠抗人Siglec-15蛋白单克隆抗体制备及其用途
CN111875708B (zh) * 2020-05-28 2021-05-04 浙江康佰裕生物科技有限公司 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用

Also Published As

Publication number Publication date
IL305409A (en) 2023-10-01
TW202235436A (zh) 2022-09-16
EP4299591A1 (en) 2024-01-03
CN116867807A (zh) 2023-10-10
CA3209169A1 (en) 2022-09-01
AU2022225026A1 (en) 2023-09-14
WO2022179483A1 (zh) 2022-09-01
JP2024508048A (ja) 2024-02-21
US20240124576A1 (en) 2024-04-18
KR20230148420A (ko) 2023-10-24

Similar Documents

Publication Publication Date Title
CL2019002610A1 (es) Anticuerpos de unión a vista a ph ácido.
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112022021322A2 (pt) Anticorpo contra nectina-4 e aplicação do mesmo
CO2020012415A2 (es) Anticuerpos de unión a vista a ph ácido
BRPI0708519A8 (pt) vesícula semelhante ao virossoma, composição farmacêutica, uso de pelo menos uma vesícula semelhante ao virossoma, método de tratamento e/ou profilaxia de uma infecção por hiv, e, kit para induzir uma resposta imune contra uma proteína gp41 de um vírus da imunodeficiência humana
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112022007947A2 (pt) Uso de modulador de splicing para tratamento que retarda a progressão da doença de huntington
BR112017019062A2 (pt) conjugados de anticorpo-fármaco (adc) que se ligam a proteínas flt3
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
CL2022002945A1 (es) Anticuerpos de unión a vista a ph ácido (solicitud divisional de 202100012)
EP3828183A4 (en) SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112021020496A2 (pt) Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
BR112023025194A2 (pt) Anticorpos anti-sirp-alfa
BR112022026341A2 (pt) Anticorpos e métodos para o tratamento de doenças associadas à claudina
BR112023016904A2 (pt) Preparação da proteína de ligação à siglec-15 e uso da mesma
BR112022026482A2 (pt) Formulação altamente concentrada de proteínas de ligação ao antígeno do fator xii
CL2019000122A1 (es) Un derivado de oxazina para usar en la prevención de la enfermedad de alzheimer en pacientes de riesgo.
BR112022011548A2 (pt) Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina
BR112021025665A2 (pt) Uma preparação que compreende um composto de calixareno e o uso médico do mesmo, alimento, ração ou composição cosmética que compreende um composto de calixareno
BR112021016948A2 (pt) Composição que compreende lrrd2 ligado à albumina de proteína slit3 para prevenção ou tratamento de doenças relacionadas a ossos e uso de lrrd2 ligado à albumina da proteína slit3
BR112019002132A2 (pt) composições anti-retrovirais